These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 39342345)
1. Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer. Chen SF; Wang LY; Lin YS; Chen CY J Ovarian Res; 2024 Sep; 17(1):190. PubMed ID: 39342345 [TBL] [Abstract][Full Text] [Related]
2. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer. Gao J; Zhao Z; Zhang H; Huang S; Xu M; Pan H Cancer Immunol Immunother; 2023 May; 72(5):1121-1138. PubMed ID: 36336725 [TBL] [Abstract][Full Text] [Related]
3. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma. Lai J; Xu T; Yang H BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291 [TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database. Liu J; Xu W; Li S; Sun R; Cheng W Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439 [No Abstract] [Full Text] [Related]
5. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma. Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951 [TBL] [Abstract][Full Text] [Related]
6. Mast Cell-related Prognosis Signature Characterizes Immune Landscape and Predicts Prognosis of Ovarian Cancer. Li Q; Guan T; Mao J; King BP; Johnson K; Mayberry TG; Cowan BC; Wakefield MR; Fang Y; Zhao Q Anticancer Res; 2024 Jul; 44(7):2775-2786. PubMed ID: 38925849 [TBL] [Abstract][Full Text] [Related]
7. Development of a CD8+ T cell associated signature for predicting the prognosis and immunological characteristics of gastric cancer by integrating single-cell and bulk RNA-sequencing. Li J; Han T; Wang X; Wang Y; Yang R; Yang Q Sci Rep; 2024 Feb; 14(1):4524. PubMed ID: 38402299 [TBL] [Abstract][Full Text] [Related]
8. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma. Wang S; Bai H; Fei S; Miao B Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914 [TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma. Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG Biochem Genet; 2024 Oct; 62(5):3439-3466. PubMed ID: 38108937 [TBL] [Abstract][Full Text] [Related]
10. Acetylation model predicts prognosis of patients and affects immune microenvironment infiltration in epithelial ovarian carcinoma. Wang X; Li X; Wei L; Yu Y; Hazaisihan Y; Tao L; Jia W J Ovarian Res; 2024 Jul; 17(1):150. PubMed ID: 39030559 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive profiling of endocrine metabolism identifies a novel signature with robust predictive value in ovarian cancer. Yu D; Luo Y; Guo R; Ma F; Chang Y; Dang J J Gene Med; 2024 May; 26(5):e3686. PubMed ID: 38689382 [TBL] [Abstract][Full Text] [Related]
12. Single‑cell RNA sequencing reveals heterogeneity in ovarian cancer and constructs a prognostic signature for prognostic prediction and immunotherapy. Zhou S; Li H; Zhao C; Zhao W; Pan X; Jian W; Wang J Int Immunopharmacol; 2024 Oct; 140():112855. PubMed ID: 39133955 [TBL] [Abstract][Full Text] [Related]
13. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer. Peng Y; Wang H; Huang Q; Wu J; Zhang M J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063 [TBL] [Abstract][Full Text] [Related]
14. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L Front Immunol; 2022; 13():943389. PubMed ID: 36003381 [TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment. Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023 [TBL] [Abstract][Full Text] [Related]
16. Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by PDGFRB inhibitors. Yang D; Duan MH; Yuan QE; Li ZL; Luo CH; Cui LY; Li LC; Xiao Y; Zhu XY; Zhang HL; Feng GK; Liu GC; Deng R; Li JD; Zhu XF J Transl Med; 2023 Sep; 21(1):586. PubMed ID: 37658364 [TBL] [Abstract][Full Text] [Related]
17. Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma. Li Q; Huang X; Zhao Y Cancer Biother Radiopharm; 2024 Sep; 39(7):502-516. PubMed ID: 37889617 [No Abstract] [Full Text] [Related]
18. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer. Xu F; Liu T; Zhou Z; Zou C; Xu S Front Immunol; 2021; 12():749369. PubMed ID: 34745121 [TBL] [Abstract][Full Text] [Related]
19. Development and verification of a manganese metabolism- and immune-related genes signature for prediction of prognosis and immune landscape in gastric cancer. Han X; Leng C; Zhao S; Wang S; Chen S; Wang S; Zhang M; Li X; Lu Y; Wang B; Qi W Front Immunol; 2024; 15():1377472. PubMed ID: 38807601 [TBL] [Abstract][Full Text] [Related]
20. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer. Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB Front Immunol; 2023; 14():1151109. PubMed ID: 37063862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]